Molecular structure of CP 471474, CAS Number: 210755-45-6
CP 471474 (CAS 210755-45-6)
See product citations (1)
Alternate Names:
2-[[[4-(4-Fluorophenoxy)phenyl]sulfonyl]amino]-N-hydrox y-2-methylpropanamide; PF-1626077
Application:
CP 471474 is a matrix metalloprotease (MMP) inhibitor
CAS Number:
210755-45-6
Molecular Weight:
368.38
Molecular Formula:
C16H16FN2O5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
CP 471474 is a broad spectrum MMP inhibitor (IC50 values are 0.7, 0.9, 13, 16 and 1170 nM for MMP-2, MMP-13, MMP-9, MMP-3 and MMP-1 respectively). It is also a reversible inhibitor of a number of enzymes, including cytochrome P450, monoamine oxidase, and xanthine oxidase. In addition, CP 471474 has also been shown to have anticonvulsant, anti-inflammatory, anti-oxidant, anti-cancer, anti-viral, and anti-bacterial properties. In vitro studies have employed CP 471474 to study the effects of other compounds on various cell lines, enzymes, and proteins.
CP 471474 (CAS 210755-45-6) References
- Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. | Rohde, LE., et al. 1999. Circulation. 99: 3063-70. PMID: 10368126
- Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. | Li, YY. and Feldman, AM. 2001. Drugs. 61: 1239-52. PMID: 11511020
- Matrix metalloproteinase inhibition and the prevention of heart failure. | Lee, RT. 2001. Trends Cardiovasc Med. 11: 202-5. PMID: 11597832
- Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. | Lindsey, ML., et al. 2002. Circulation. 105: 753-8. PMID: 11839633
- Engineering autoactivating forms of matrix metalloproteinase-9 and expression of the active enzyme in cultured cells and transgenic mouse brain. | Fisher, KE., et al. 2002. Biochemistry. 41: 8289-97. PMID: 12081477
- Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in Guinea pigs. | Selman, M., et al. 2003. Chest. 123: 1633-41. PMID: 12740284
- Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. | Fang, L., et al. 2007. J Mol Cell Cardiol. 43: 535-44. PMID: 17689559
- Macrophage metalloelastase (MMP-12) as a target for inflammatory respiratory diseases. | Lagente, V., et al. 2009. Expert Opin Ther Targets. 13: 287-95. PMID: 19236151
- Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone. | Mak, IW., et al. 2010. Hum Pathol. 41: 1320-9. PMID: 20573369
- Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition: imprisoning instead of poisoning cancer cells. | Meng, H., et al. 2012. Nanomedicine. 8: 136-46. PMID: 21930111
- MMP-9 signaling in the left ventricle following myocardial infarction. | Iyer, RP., et al. 2016. Am J Physiol Heart Circ Physiol. 311: H190-8. PMID: 27208160
- Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism. | Marcos-Contreras, OA., et al. 2016. Blood. 128: 2423-2434. PMID: 27531677
- Nanoliter Quantitative High-Throughput Screening with Large-Scale Tunable Gradients Based on a Microfluidic Droplet Robot under Unilateral Dispersion Mode. | Wei, Y., et al. 2019. Anal Chem. 91: 4995-5003. PMID: 30813716
Inhibitor of:
MMP-13, MMP-2, MMP-3, MMP-8, MMP-9, Protease, and PYGL.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CP 471474, 10 mg | sc-361157 | 10 mg | $200.00 |